Strides Pharma Science DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.86×	0.86×	7.42×	−1.60×	231.55×
	1.00×	0.92×	0.79×	0.11×	−0.00×
	14.2%	14.9%	13.4%	12.9%	5.1%
	0.75×	0.75×	0.77×	0.65×	0.54×
	2.16×	2.20×	2.34×	2.82×	3.06×
	19.8%	19.5%	141.9%	−4.3%	−9.5%
	19.7%	19.7%	153.7%	−3.3%	−8.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

STAR₹1,001.10

Strides Pharma Science Ltd.

· Pharma & Health

₹ CrorePeersSPARC SUPRIYA SHILPAMED THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹9,227 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	231.55	-1.60	7.42	0.86	0.86
Interest Burden (Pretax/EBIT) ×	-0.00	0.11	0.79	0.92	1.00
EBIT Margin %	5.07	12.90	13.37	14.88	14.17
Asset Turnover ×	0.54	0.65	0.77	0.75	0.75
Financial Leverage (Assets/Equity) ×	3.06	2.82	2.34	2.20	2.16
ROE (5-step product, year-end total equity) %	-9.50	-4.27	141.90	19.51	19.78
ROE (owners' profit / average owners' equity) %	-8.87	-3.26	153.65	19.66	19.66

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.